CMPS Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.398

-36.86%

-0.475

+137.5%

-0.553

+34.96%

Estimates Revision

Stock Price

Go Up

+12.11%

In Past 3 Month

5 Analyst Rating

Wall Street analysts forecast CMPS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CMPS is 21.00 USD with a low forecast of 12.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

12.00

Averages

21.00

High

40.00

Current: 0.000

Low

12.00

Averages

21.00

High

40.00

Oppenheimer

Perform -> Outperform

upgrade

$15

2025-12-09

Reason

Oppenheimer

Price Target

$15

2025-12-09

upgrade

Perform -> Outperform

Reason

Oppenheimer upgraded Compass Pathways to Outperform from Perform with a $15 price target.

Oppenheimer

Perform -> Outperform

upgrade

$15

2025-12-09

Reason

Oppenheimer

Price Target

$15

2025-12-09

upgrade

Perform -> Outperform

Reason

Oppenheimer upgraded Compass Pathways to Outperform from Perform with a $15 price target. The firm is citing it higher conviction that the company's COMP360 will "lead the revolution of psychedelic medicine" for neuropsychiatry, the analyst tells investors in a research note. COMP360, or psilocybin, should become the first ever FDA-approved classical psychedelic therapy for treatment-resistant depression patients, where the firm sees a $1.5B peak sales opportunity, the firm added.

Citizens JMP

Reni Benjamin

Outperform

initiated

$10

2025-12-03

Reason

Citizens JMP

Reni Benjamin

Price Target

$10

2025-12-03

initiated

Outperform

Reason

Citizens JMP analyst Reni Benjamin initiated coverage of Compass Therapeutics with an Outperform rating and $10 price target. The firm says the company's most-advanced candidate, tovecimig, recently demonstrated a 17% overall response rate in combination with paclitaxel as a treatment for biliary tract cancers versus 5% for the paclitaxel comparison arm in a pivotal Phase 2/3 study. The analyst also believes CTX-10726 "could be a diamond in the rough" for Compass.

H.C. Wainwright

Buy

downgrade

$45 -> $40

2025-08-04

Reason

H.C. Wainwright

Price Target

$45 -> $40

2025-08-04

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Compass Pathways to $40 from $45 and keeps a Buy rating on the shares. Compass confirmed that no further development is planned in anorexia nervosa following completion of the Phase 2 trial, the analyst tells investors in a research note. As such, the firm removed the indication from its model post the Q2 report.

H.C. Wainwright

Buy

maintain

2025-07-15

Reason

H.C. Wainwright

Price Target

2025-07-15

maintain

Buy

Reason

H.C. Wainwright reiterates a Buy rating on shares of Compass Pathways, telling investors in a research note that the Phase 3 COMP005 trial delivered a regulatory win for COMP360 and the Phase 3 COMP006 trial is positioned to build on that success. The ongoing COMP006 trial, which is exploring a fixed repeat dosing regimen, is on track for a 26-week data readout in 2H26 and is expected to provide insight into durability and re-dosing strategy with COMP360, the firm says.

Canaccord

Sumant Kulkarni

Buy

maintain

$15

2025-06-24

Reason

Canaccord

Sumant Kulkarni

Price Target

$15

2025-06-24

maintain

Buy

Reason

Canaccord analyst Sumant Kulkarni said the weakness in Compass Pathways following the release of top-line results from its eagerly-awaited COMP005 Phase 3 trial for COMP360 (psilocybin) in treatment-resistant depression (TRD). COMP006, a second Phase 3 trial, is a buying opportunity. Canaccord believes updates from the FDA could eventually move the stock and there is no change tpo their model pending additional data. Canaccord reiterates its Buy rating and $15 price target on Compass Pathways shares.

Valuation Metrics

The current forward P/E ratio for Compass Pathways PLC (CMPS.O) is -3.34, compared to its 5-year average forward P/E of -6.97. For a more detailed relative valuation and DCF analysis to assess Compass Pathways PLC 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.97

Current PE

-3.34

Overvalued PE

0.06

Undervalued PE

-14.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-4.61

Current EV/EBITDA

-2.50

Overvalued EV/EBITDA

1.29

Undervalued EV/EBITDA

-10.51

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

89.57

Current PS

0.00

Overvalued PS

487.93

Undervalued PS

-308.80

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 302.54% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

CMPS News & Events

Events Timeline

No data

News

9.0

01-07Newsfilter

Compass Receives FDA Approval for COMP360 PTSD Clinical Trial

7.5

01-06Businesswire

Compass Pathways Partners with Radial Health to Advance COMP360 Treatment Models

2.0

2025-12-10NASDAQ.COM

Post-Market Surge: Stoke Therapeutics, Alpha Tau Medical, and Compass Pathways Top Biotech Gainers

People Also Watch

Frequently Asked Questions

What is Compass Pathways PLC (CMPS) stock price today?

The current price of CMPS is 7.22 USD — it has decreased -5.25 % in the last trading day.

What is Compass Pathways PLC (CMPS)'s business?

Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in treating mental health conditions focused on rapid and durable responses through the development of its investigational COMP360 psilocybin treatment. COMP360 is its psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.

What is the price predicton of CMPS Stock?

What is Compass Pathways PLC (CMPS)'s revenue for the last quarter?

Compass Pathways PLC revenue for the last quarter amounts to -40.54M USD, decreased -15.37 % YoY.

What is Compass Pathways PLC (CMPS)'s earnings per share (EPS) for the last quarter?

Compass Pathways PLC. EPS for the last quarter amounts to USD, decreased -100.00 % YoY.

What changes have occurred in the market's expectations for Compass Pathways PLC (CMPS)'s fundamentals?

The market is revising No Change the revenue expectations for CMPS for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 12.11%.

How many employees does Compass Pathways PLC (CMPS). have?

Compass Pathways PLC (CMPS) has 166 emplpoyees as of January 10 2026.

What is Compass Pathways PLC (CMPS) market cap?

Today CMPS has the market capitalization of 693.24M USD.